Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Review

Clinical Trial, Phase I

Clinical Trial

Publication Year

From

Quick links

Individual year

2025

2017

2015

2013

2012

2005

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for

""Phosphatidylethanolamine Binding Protein""[mesh_terms]

6 Results

Searching titles within these results

Multi-omic analysis constructs ferroptosis subtypes and risk signature and reveals that PEBP1 is an important tumor suppressor in kidney cancer.

Shuaiqi Chen, Xizi Cheng, Zeyu Li, Huijun Fan, Xiangdong Xue, Kuo Ma, Jingxian Li, Feng Zhu

Human cell 2025;38(6):173

Full Text

Abstract

Florigenic and antiflorigenic signaling in plants.

Ianis G Matsoukas, Andrea J Massiah, Brian Thomas

Plant & cell physiology 2013;53(11):1827-42

Full Text

Abstract

Functional evolution of phosphatidylethanolamine binding proteins in soybean and Arabidopsis.

Tian Tang, Tengfei Liu, Yunfeng Liu, Zhengkui Zhou, Zheng Wang, Qing Li, Yuanyuan Ji, Congcong Li, Chao Fang, Min Wang, Mian Wu, Yanting Shen, Jianxin Ma, Zhixi Tian

The Plant cell 2015;27(2):323-36

Free Full Text

Abstract

Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.

Yin Chen, Yaxin Zheng, Qinglin Jiang, Feifei Qin, Yonghui Zhang, Leilei Fu, Gu He

European journal of medicinal chemistry 2017;127():997-1011

Full Text

Abstract

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Dirk Strumberg, Heike Richly, Ralf A Hilger, Norbert Schleucher, Sonke Korfee, Mitra Tewes, Markus Faghih, Erich Brendel, Dimitris Voliotis, Claus G Haase, Brian Schwartz, Ahmad Awada, Rudolf Voigtmann, Max E Scheulen, Siegfried Seeber

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(5):965-72

Full Text

Abstract

Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.

Giuseppe Pasqualetti, Simona Ricciardi, Valentina Mey, Mario Del Tacca, Romano Danesi

Lung cancer (Amsterdam, Netherlands) 2012;74(2):197-205

Full Text

Abstract

Results: 1 – 6 / 6

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Phosphatidylethanolamine Binding Protein""[mesh_terms]

Multi-omic analysis constructs ferroptosis subtypes and risk signature and reveals that PEBP1 is an important tumor suppressor in kidney cancer.

Florigenic and antiflorigenic signaling in plants.

Functional evolution of phosphatidylethanolamine binding proteins in soybean and Arabidopsis.

Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells.

Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.

Results for

""Phosphatidylethanolamine Binding Protein""[mesh_terms]